Abstract
Purpose: Neoadjuvant chemotherapy (NACT) for early breast cancer (EBC) is indicated for downstaging tumours to allow for breast conserving surgery (BCS). Furthermore, pCR is a surrogate marker for outcome which allows for tailoring of adjuvant treatment to optimise outcomes, especially for Her2(+) and triple negative. This retrospective review aims to provide real world data, regarding downstaging rates, pCR rates and correlation between pCR rates and post-NACT MRI.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
